On June 5, 2025, CG Oncology, Inc. held its Annual Meeting where stockholders elected three directors for a term until 2028 and ratified Ernst & Young LLP as the accounting firm for 2025. A total of 76,221,857 shares were eligible to vote, with significant support for the proposals.